News | 29 January 2023
Glenmark Life Sciences posts Q3 FY23 PAT at Rs. 104.99 Cr
The company has reported total income of Rs. 547.33 crores during the period ended December 31, 2022
The company has reported total income of Rs. 547.33 crores during the period ended December 31, 2022
The company has reported total income of Rs. 78.50 crores during the period ended December 31, 2022
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
The company has reported total income of Rs. 211.36 crores during the period ended December 31, 2022
The WHO has urged China to increase adoption of mRNA vaccines, given their high efficacy against variant strains.
Biocon Foundation has pioneered a mHealth-technology-based (mobile health) oral cancer screening program in India
SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection
The company has reported total income of Rs. 6848.5 crores during the period ended December 31, 2022
The company has reported total income of Rs. 2481 crores during the period ended December 31, 2022
Cell sorting technology supports researchers advancing new therapies
It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV
The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
The National Institute of Pharmacy and Nutrition, Hungary has issued 'Certificate of GMP Compliance of Manufacturer' for IOL Chemicals and Pharmaceuticals Limited's products.
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
Subscribe To Our Newsletter & Stay Updated
